针对线粒体代谢来克服乳腺癌中的荷尔蒙抵抗性
Abbas S Neamah1, Fadhel M Lafta2, Al-Hassan Soliman Wadan3
1Department of Biology College of Sciences, University of Baghdad, Baghdad, Iraq. Abbas.Saad2102@sc.uobaghdad.edu.iq.
激素耐药性是激素受体阳性乳腺癌 (HR+ BC) 的一个主要挑战. 结合激素治疗和向抑制剂的新疗法,专注于抵抗机制,旨在改善患者的结果.
科学领域:
- 癌症学
- 内分泌学
- 分子生物学
背景情况:
- 激素受体阳性 (HR+) 乳腺癌 (BC) 是最常见的亚型.
- 虽然内分泌疗法是标准的治疗方法,
- 在许多患者中,耐药性导致治疗失败和疾病进展.
研究的目的:
- 审查HR+BC的耐药性机制.
- 讨论克服抗药性的新疗法.
- 强调个性化医疗方法的重要性.
主要方法:
- 对HR+BC抗性机制的当前文献的综述.
- 针对抗药性途径的新疗法分析.
- 专注于分子分析和生物标志物识别.
主要成果:
- 关键的抵抗机制包括雌激素受体 (ER) 突变,PI3K/Akt/mTOR通路激活,以及瘤异质性.
- 新兴的疗法包括将激素治疗与向抑制剂结合起来.
- 新的方法包括线粒体破坏,表观遗传调节和瘤微环境的向.
结论:
- 了解多因素耐药性对于改善HR+BC结果至关重要.
- 一种多学科的,基于机制的方法至关重要.
- 个性化医疗策略有望恢复治疗敏感性并提高存活率.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Mitogens and the Cell Cycle
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
